ClinicalTrialsFinder
RecruitingNCT07198256

AI-assisted Diagnosis of Malignant Brain Tumors

Research on AI-assisted Diagnosis of Common Malignant Brain Tumors Based on Magnetic Resonance Imaging

Sponsor

Second Affiliated Hospital, School of Medicine, Zhejiang University

Enrollment

3,000 participants

Start Date

Sep 1, 2025

Study Type

OBSERVATIONAL

Conditions

Brain Metastases, AdultLymphomaGliomasBrain Tumor Adult

Summary

This study aims to establish a large-scale, multi-center MRI database for malignant brain tumors. It will develop an artificial intelligence system for the segmentation and classification of multiple subtypes of brain tumors (including glioma, metastatic tumor and lymphoma et al.) using deep learning technology. This will address the issues of small sample sizes and limited classification performance in existing methods, thereby improving the accuracy of non-invasive preoperative diagnosis, reducing the need for biopsies, and having significant clinical translational value.

Eligibility

Min Age: 18 YearsMax Age: 100 Years

Plain Language Summary

Simplified for easier understanding

This study is developing and testing an artificial intelligence (AI) tool to help doctors diagnose malignant brain tumors — including gliomas, brain metastases, and brain lymphoma — using MRI scans taken before surgery. The goal is to improve the accuracy and speed of diagnosis. **You may be eligible if...** - You are 18 years or older - You have been diagnosed with a glioma, brain metastasis, or brain lymphoma confirmed by pathology - You had a complete MRI before surgery **You may NOT be eligible if...** - Your MRI images are of poor quality - You have had previous brain surgery or radiotherapy - You have other brain lesions besides the primary tumor Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Locations(2)

2nd Affiliated Hospital, School of Medicine, Zhejiang University

Hangzhou, Zhejiang, China

Zhejiang Cancer Hospital

Hangzhou, Zhejiang, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07198256

Related Trials

Cognitive Aftereffects of Neurotoxicity in Children and Young Adults With Relapsed/Refractory Hematologic Malignancies Who Receive CAR T-cell Therapy

NCT052379863 locations

Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma

NCT047398131 location

Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-HodgkinLymphomas

NCT032585671 location

A Study of Pembrolizumab in Japanese Pediatric Participants With Solid Tumors or Lymphomas and Japanese Adult Participants With Merkel Cell Carcinoma (MK-3475-G21/KEYNOTE-G21)

NCT073023473 locations

Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors

NCT064413315 locations